Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Jeffrey J. Crowley, Richard G. Langley, Kenneth B. Gordon, Andreas Pinter, Laura K. Ferris, Simone Rubant, Huzefa Photowala, Zhenyi Xue, Tianshuang Wu, Tianyu Zhan, Stefan Beeck, Megha Shah, Richard B. Warren
Dive into the research topics of 'Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study'. Together they form a unique fingerprint.